CA2834286A1 - Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders - Google Patents
Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders Download PDFInfo
- Publication number
- CA2834286A1 CA2834286A1 CA2834286A CA2834286A CA2834286A1 CA 2834286 A1 CA2834286 A1 CA 2834286A1 CA 2834286 A CA2834286 A CA 2834286A CA 2834286 A CA2834286 A CA 2834286A CA 2834286 A1 CA2834286 A1 CA 2834286A1
- Authority
- CA
- Canada
- Prior art keywords
- 4alkyl
- phenyl
- group
- 4alkenyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010003805 Autism Diseases 0.000 title claims abstract 7
- 208000020706 Autistic disease Diseases 0.000 title claims abstract 7
- 208000024827 Alzheimer disease Diseases 0.000 title claims 3
- 208000023105 Huntington disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 75
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 60
- 125000001424 substituent group Chemical group 0.000 claims 40
- -1 stereoisomers Chemical class 0.000 claims 34
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 25
- 150000002367 halogens Chemical class 0.000 claims 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 10
- 125000003368 amide group Chemical group 0.000 claims 10
- 150000001412 amines Chemical class 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 150000001204 N-oxides Chemical class 0.000 claims 9
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 5
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000003956 synaptic plasticity Effects 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 101150037123 APOE gene Proteins 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 102100029470 Apolipoprotein E Human genes 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 102000017692 GABRA5 Human genes 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 claims 1
- 101001001388 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-5 Proteins 0.000 claims 1
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims 1
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 102100024622 Proenkephalin-B Human genes 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 108010074732 preproenkephalin Proteins 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical group C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479593P | 2011-04-27 | 2011-04-27 | |
| US61/479,593 | 2011-04-27 | ||
| US201161527744P | 2011-08-26 | 2011-08-26 | |
| US61/527,744 | 2011-08-26 | ||
| PCT/US2012/035547 WO2012149389A2 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2834286A1 true CA2834286A1 (en) | 2012-11-01 |
Family
ID=47073094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2834286A Abandoned CA2834286A1 (en) | 2011-04-27 | 2012-04-27 | Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140107037A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3679931A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6035326B2 (cg-RX-API-DMAC7.html) |
| KR (5) | KR20180095096A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108283712A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012249397B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013027554A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2834286A1 (cg-RX-API-DMAC7.html) |
| EA (2) | EA201790653A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1258231A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX357761B (cg-RX-API-DMAC7.html) |
| SG (2) | SG194230A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012149389A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033757A1 (en) | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| BR112012020142A2 (pt) | 2010-02-11 | 2020-08-18 | Northwestern University | moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos. |
| CN105026401A (zh) | 2013-01-29 | 2015-11-04 | 诺雷克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| ES2935352T3 (es) | 2013-01-29 | 2023-03-06 | Aptinyx Inc | Moduladores de receptores NMDA de espiro-lactama y sus usos |
| MX375286B (es) | 2013-01-29 | 2025-03-06 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| BR112015018094A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor nmda de espiro-lactama e usos dos mesmos |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| JP6603668B2 (ja) * | 2013-10-28 | 2019-11-06 | ノーレックス インコーポレイテッド | Ｎｍｄａ受容体モジュレーター及びプロドラッグ、塩、並びにこれらの使用 |
| CN111920412A (zh) * | 2013-12-13 | 2020-11-13 | 西北大学 | 治疗脑部病症或鉴定与其相关的生物标记的方法 |
| CN105327349A (zh) * | 2014-06-18 | 2016-02-17 | 上海翰森生物医药科技有限公司 | Nmda受体拮抗剂的医药用途及其药物组合物 |
| JP6688748B2 (ja) * | 2014-06-23 | 2020-04-28 | ノースウェスタン ユニバーシティ | 片頭痛の治療または改善方法 |
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102128675B1 (ko) | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| JP2019527235A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| KR102503590B1 (ko) | 2016-08-01 | 2023-02-24 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| SG11201900551WA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| CA3031563C (en) | 2016-08-01 | 2023-12-05 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| EA201990424A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
| SG11202007256PA (en) | 2018-01-31 | 2020-08-28 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| KR102415692B1 (ko) | 2020-09-01 | 2022-07-05 | 건국대학교 글로컬산학협력단 | 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| JP2005518411A (ja) * | 2002-01-16 | 2005-06-23 | エンド ファーマシューティカルズ インコーポレーテッド | 中枢神経系の障害を治療する製薬組成物及び方法 |
| US20060063707A1 (en) * | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| RS52471B (sr) * | 2005-03-24 | 2013-02-28 | Emory University | Režimi doziranja za lečenje traumatske povrede mozga progesteronom |
| US9783851B2 (en) * | 2008-02-20 | 2017-10-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| WO2010033757A1 (en) * | 2008-09-18 | 2010-03-25 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
| PL2485751T3 (pl) * | 2009-10-05 | 2014-10-31 | Univ Northwestern | GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie |
-
2012
- 2012-04-27 EP EP20151676.2A patent/EP3679931A3/en not_active Withdrawn
- 2012-04-27 JP JP2014508130A patent/JP6035326B2/ja not_active Expired - Fee Related
- 2012-04-27 EP EP12777016.2A patent/EP2701721A4/en not_active Ceased
- 2012-04-27 SG SG2013079603A patent/SG194230A1/en unknown
- 2012-04-27 KR KR1020187022910A patent/KR20180095096A/ko not_active Ceased
- 2012-04-27 EA EA201790653A patent/EA201790653A1/ru unknown
- 2012-04-27 KR KR1020197008907A patent/KR20190037359A/ko not_active Ceased
- 2012-04-27 EA EA201391581A patent/EA029999B1/ru unknown
- 2012-04-27 CA CA2834286A patent/CA2834286A1/en not_active Abandoned
- 2012-04-27 CN CN201711451914.XA patent/CN108283712A/zh active Pending
- 2012-04-27 MX MX2013012526A patent/MX357761B/es active IP Right Grant
- 2012-04-27 KR KR1020207011211A patent/KR20200043534A/ko not_active Ceased
- 2012-04-27 KR KR1020217011613A patent/KR20210046843A/ko not_active Ceased
- 2012-04-27 US US14/114,376 patent/US20140107037A1/en not_active Abandoned
- 2012-04-27 KR KR1020137031028A patent/KR20140043078A/ko not_active Ceased
- 2012-04-27 SG SG10202010665YA patent/SG10202010665YA/en unknown
- 2012-04-27 BR BR112013027554A patent/BR112013027554A2/pt not_active Application Discontinuation
- 2012-04-27 AU AU2012249397A patent/AU2012249397B2/en not_active Ceased
- 2012-04-27 CN CN201280027349.3A patent/CN103974712A/zh active Pending
- 2012-04-27 WO PCT/US2012/035547 patent/WO2012149389A2/en not_active Ceased
-
2016
- 2016-04-14 US US15/098,985 patent/US20170049845A1/en not_active Abandoned
-
2018
- 2018-10-23 US US16/168,242 patent/US20190209642A1/en not_active Abandoned
-
2019
- 2019-01-14 HK HK19100591.2A patent/HK1258231A1/zh unknown
-
2020
- 2020-05-05 US US16/867,324 patent/US20210169964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103974712A (zh) | 2014-08-06 |
| WO2012149389A2 (en) | 2012-11-01 |
| MX357761B (es) | 2018-07-23 |
| AU2012249397A1 (en) | 2013-11-07 |
| EA029999B1 (ru) | 2018-06-29 |
| KR20140043078A (ko) | 2014-04-08 |
| BR112013027554A2 (pt) | 2016-09-06 |
| EA201391581A1 (ru) | 2014-05-30 |
| MX2013012526A (es) | 2014-04-16 |
| EP3679931A2 (en) | 2020-07-15 |
| US20210169964A1 (en) | 2021-06-10 |
| EA201790653A1 (ru) | 2017-07-31 |
| KR20210046843A (ko) | 2021-04-28 |
| WO2012149389A3 (en) | 2014-05-08 |
| KR20200043534A (ko) | 2020-04-27 |
| EP2701721A4 (en) | 2015-12-16 |
| KR20190037359A (ko) | 2019-04-05 |
| HK1258231A1 (zh) | 2019-11-08 |
| EP2701721A2 (en) | 2014-03-05 |
| US20190209642A1 (en) | 2019-07-11 |
| EP3679931A3 (en) | 2020-10-14 |
| AU2012249397B2 (en) | 2017-03-30 |
| US20140107037A1 (en) | 2014-04-17 |
| SG10202010665YA (en) | 2020-11-27 |
| US20170049845A1 (en) | 2017-02-23 |
| CN108283712A (zh) | 2018-07-17 |
| SG194230A1 (en) | 2013-12-30 |
| KR20180095096A (ko) | 2018-08-24 |
| JP2014520072A (ja) | 2014-08-21 |
| JP6035326B2 (ja) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2834286A1 (en) | Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders | |
| JP2014520072A5 (cg-RX-API-DMAC7.html) | ||
| CA3019663C (en) | IVACAFTOR ANALOGUES CONTAINING SILICONE ATOMS | |
| KR102391134B1 (ko) | 벤조퀴놀린 화합물을 제조하는 방법 | |
| JP4511023B2 (ja) | 神経細胞ニコチン性α７レセプタアゴニストとしてのベンジリデン−およびシンナミリデン−アナバセイン | |
| UA109802C2 (xx) | Похідні біцикло$3.2.1]октиламіду та їх застосування | |
| AU2014212465A1 (en) | S1P modulating agents | |
| JP2013544277A5 (cg-RX-API-DMAC7.html) | ||
| EP2938616A1 (en) | The present invention relates to process for the preparation of tofacitinib and intermediates thereof. | |
| PH12015501145A1 (en) | Peptides as oxytocin agonists | |
| JP2010024243A (ja) | 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体 | |
| AU608692B2 (en) | Tetrazole excitatory amino acid receptor antagonists | |
| US12227479B2 (en) | Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury | |
| JP2017525684A5 (cg-RX-API-DMAC7.html) | ||
| WO2013157511A1 (ja) | アリールアミノピラゾール誘導体 | |
| JPWO2019163917A1 (ja) | Ｓ１ｐ５受容体作動活性を有する化合物 | |
| DD279674A5 (de) | Verfahren zur herstellung von hydrierten 1-benzooxacycloalkyl-pyridincarbonsaeureverbindungen | |
| NZ575573A (en) | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | |
| HRP20110093T1 (hr) | Kristalna baza escitaloprama i orodisperzibilne tablete koje sadrže bazu escitaloprama | |
| JP2010527958A (ja) | Ｓ１ｐ受容体モジュレーターとして有用なベンズアミド | |
| CN1230959A (zh) | N－(2－苯并噻唑基)－1－哌啶乙胺衍生物,其制备方法及其在治疗中的应用 | |
| AU2011280031B2 (en) | Synthesis and use of Kinase inhibitors | |
| JP2013529687A5 (cg-RX-API-DMAC7.html) | ||
| JP2016222628A (ja) | デュロキセチン塩酸塩の製造方法 | |
| WO2022010882A1 (en) | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170131 |
|
| FZDE | Discontinued |
Effective date: 20220512 |
|
| FZDE | Discontinued |
Effective date: 20220512 |